Injectable BPC-157 is preferred for musculoskeletal injuries, as it allows targeted delivery to the affected area and higher systemic bioavailability
Can really feel the difference after getting the shot
If neurological symptoms are present (such as paraesthesia, ataxia, cognitive changes, or visual disturbances), more intensive treatment is required
An alarming or concerning B12 level is below 200 picograms per milliliter (pg/mL)
Since 2010, it has technically remained the only truly FDA-approved treatment specifically indicated for the treatment of chronic migraine prevention, up until Qulipta (Atogepant) became the first and only pill to receive FDA approval for chronic migraine in 2023
Once all the water is in, gently remove the syringe